Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00509457
Status:
COMPLETED
Last Update Posted:
2011-07-01
First Post:
2007-07-20
Brief Title:
GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer NSCLC
Sponsor:
Oslo University Hospital
Organization:
Oslo University Hospital
Study Overview
Official Title:
Immunotherapy in Patients With Non-small Cell Lung Cancer NSCLC A Phase II Study of GV 1001 Telomerase Peptide Vaccination in Patients With Locally Advanced NSCLC
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To examine the safety and efficacy of telomerase peptide vaccination stimulation of the immune system in patients with NSCLC after having been treated with conventional therapy with radiotherapy and docetaxel as a radiosensitizer
Detailed Description:
Survival in patients with locally advanced inoperable NSCLC may be improved if local control can be achieved with concurrent chemo radiotherapy After completed standard chemo-and radiation therapy the safety and efficacy of vaccination therapy will be measured as time to progression after treatment with GV1001 Analysis of changes in T-cell subpopulations and cytokines in peripheral blood will be performed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-50 DNR | None | None | None |